Dupixent bests placebo in clinical, histological outcomes in patients with EoE

CHARLOTTE, N.C. — Dupilumab improved clinical, symptomatic, histologic and endoscopic outcomes among patients treated for eosinophilic esophagitis, according to study results presented at the ACG Annual Scientific Meeting.“EoE is a chronic, progressive, type 2 inflammatory disease of the esophagus, leading to symptoms of esophageal dysfunction that can substantially affect quality of life. Some current treatment options lack specificity, present adherence challenges or may offer suboptimal long-term disease control,” Evan S. Dellon, MD, MPH, FACG, professor of medicine andRead More

Generated by Feedzy